ROSTOV OFAS PREVENTED PHARMACEUTICAL CARTEL WITH AN INCOME OF MORE THAN 120 MILLION RUB

02-09-2020 | 09:44

Illegal income of Danta LLC and Company Organika LLC was obtained by colluding at 48 auctions for the supply of medicines

Rostov OFAS found that auctions where Danta LLC and Company Organika LLC participated in were held for the supply of medicines to public health institutions in the Southern Federal district.

As a result of the collusion[1], the companies signed contracts at 48 auctions with a minimum reduction in the initial price for a total amount of more than 120 million rubles.

It should be noted that the Rostov OFAS detected collusion between two companies during proactive monitoring of electronic trading. In the context of countering the spread of coronavirus infection, the proactive method of detecting cartels has proven effectiveness: it allows employees of antimonopoly authorities to obtain the necessary set of evidence of collusion remotely.

Rostov OFAS has initiated a procedure to bring the collusion of companies to administrative responsibility under part 2 article 14.32 of the Administrative Code, which establishes the penalty for such anticompetitive behavior,” said Natalia Kozhemyako, Deputy Head – Head of the Anti-Cartel Division of the Rostov OFAS.

“The healthcare sector is still one of the most cartelized in the territory of our country. Additional budget funds that the state allocates to provide patients with the necessary medicines are actually “eaten” by anti-competitive agreements, said Andrey Tenishev, Head of the Anti-Cartel Department of the FAS Russia. In order to prevent such illegal activities and the possibility of recurrences, the Antimonopoly Authority appoints significant fines to violators and transmits materials to law enforcement agencies for making a decision on initiating criminal proceedings against unfair business.”

 

[1] in violation of the Paragraph 2 of the Part 1 of the Article 11 of the Law on Protection of Competition



Site Map

News & Events Press Releases Media Releases Image Library About the FAS Russia What We Do General Information Mission, Goals, Values Priority Setting Institutional Memory Stakeholders Engagement Center for Education and Methodics Our History Our Structure Powers of Head and Deputy Heads Our Ratings GCR Using our website International Cooperation Treaties & Agreements OECD Competition Committee OECD meetings 2013 OECD meetings 2014 OECD meetings 2015 OECD meetings 2016 OECD meetings 2017 OECD meetings 2018 FAS Annual Reports OECD-GVH RCC RCC Newsletter ICAP Council on Advertising Headquarters for Joint Investigations UNCTAD 13th session IGE UNCTAD Resolution Russian contributions 14th session IGE UNCTAD Resolution Russian contributions 15th session IGE UNCTAD 16th session IGE UNCTAD 17th session IGE UNCTAD 18th session IGE UNCTAD EEU Model Law on Competition ICN BRICS BRICS Conferences Documents The BRICS Competition Law and Policy Centre (BRICS Competition Centre) BRICS Working Groups for the research of competition issues in socially important markets The Working Group for Research on the Competition Issues in the Pharmaceutical Markets Chair: Russia The Working Group for Research on food value chains Chair: South Africa The Working Group for Research on the Competition Issues in the Automobile Markets Co-chaired: India, South Africa The Working Group for Research on the Competition Issues in the Digital Markets Co-chairs: Brazil, Russia BRICS Coordination Committee on antimonopoly policy EU APEC Competition Policy and Law Group Annual meetings Projects ERRA Full Members Organizational Structure Archive Working Group on Investigating Issues on Pricing in the Oil and Oil Product Markets and Methods of their Functioning Meetings Working Group for Studying Competition Problems in the Pharmaceutical Sector Working Group on Research of Competition Issues in the Market of International Telecommunications (Roaming) Document Library Legislation Reports & Analytics Cases & decisions Contacts Give feedback Contact us Links Authorities Worldwide COVID-19